Forside  
Velg data du ønsker med i utskriften
Tittel Versjon Status
IS-nr ISBN
Revisjonsdato Publiseringsdato
Utgiver(e) Publikasjonstype
  • Norsk tittel - Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av lungekreft, mesoteliom og thymom
  • Engelsk tittel -
  • Versjon - 16. utgave
  • Status - Publisert
  • IS-nr - 2860
  • ISBN - 978-82-8081-608-5
  • DOI -
  • Revisjonsdato - 28.04.2020
  • Neste revisjon -
  • Publikasjonsdato - 01.12.2007
  • Utløpsdato -
  • Utgiver(e) - Helsedirektoratet
  • Redaktør -
  • Publikasjonstype - Nasjonale retningslinjer
  1. Christensen, N.L., et al., Lung cancer guidelines in Sweden, Denmark, Norway and Finland: a comparison. Acta Oncol, 2017. 56(7): p. 943-948.

  2. Ferlay, J., et al., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015. 136(5): p. E359-86.

  3. Brustugun, O.T., B. Møller, and A. Helland, Years of life lost as a measure of cancer burden on a national level. Br J Cancer, 2014. 111(5): p. 1014-20.

  4. Sagerup, C.M., et al., Sex-specific trends in lung cancer incidence and survival: a population study of 40,118 cases. Thorax, 2011. 66(4): p. 301-7.

  5. Sagerup, C.M., et al., Increasing age and carcinoma not otherwise specified: a 20-year population study of 40,118 lung cancer patients. J Thorac Oncol, 2012. 7(1): p. 57-63.

  6. Brustugun, O.T., et al., Substantial nation-wide improvement in lung cancer relative survival in  Norway from 2000 to 2016   Lung Cancer, 2018. 122: p. 138-145.

  7. Haldorsen, T., A. Andersen, and P. Boffetta, Smoking-adjusted incidence of lung cancer by occupation among Norwegian men. Cancer Causes Control, 2004. 15(2): p. 139-47.

  8. Helland, A. and O.T. Brustugun, [Lung cancer in smokers and never-smokers]. Tidsskr Nor Laegeforen, 2009. 129(18): p. 1859-62.

  9. Sagerup, C.M., et al., Human papilloma virus detection and typing in 334 lung cancer patients. Acta Oncol, 2014. 53(7): p. 952-7.

  10. Bugge, A.S., et al., Cause-specific death after surgical resection for early-stage non-small-cell lung cancer. Eur J Cardiothorac Surg, 2018. 53(1): p. 221-227.

  11. Wijn, D.H., et al., Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events. Eur J Cancer, 2018. 104: p. 182-187.

  12. Schoser, B., et al., Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer. J Neurol, 2017. 264(9): p. 1854-1863.

  13. de Langen, A.J., et al., The size of mediastinal lymph nodes and its relation with metastatic involvement: a meta-analysis. Eur J Cardiothorac Surg, 2006. 29(1): p. 26-9.

  14. Gunluoglu, M.Z., et al., The validity of preoperative lymph node staging guidelines of European Society of Thoracic Surgeons in non-small-cell lung cancer patients. Eur J Cardiothorac Surg, 2011. 40(2): p. 287-90.

  15. Vansteenkiste, J., et al., Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2013. 24 Suppl 6: p. vi89-98.

  16. De Leyn, P., et al., Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg, 2014. 45(5): p. 787-98.

  17. Brunelli, A., et al., Minute ventilation-to-carbon dioxide output (VE/VCO2) slope is the strongest predictor of respiratory complications and death after pulmonary resection. Ann Thorac Surg, 2012. 93(6): p. 1802-6.

  18. Salati, M. and A. Brunelli, Preoperative assessment of patients for lung cancer surgery. Curr Opin Pulm Med, 2012. 18(4): p. 289-94.

  19. Adabag, A.S., et al., Preoperative pulmonary function and mortality after cardiac surgery. Am Heart J, 2010. 159(4): p. 691-7.

  20. Brunelli, A., et al., ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J, 2009. 34(1): p. 17-41.

  21. Lim, E., et al., Cardiopulmonary exercise testing for the selection of patients undergoing surgery for lung cancer: friend or foe? Thorax, 2010. 65(10): p. 847-9.

  22. Postmus, P.E., et al., Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2017. 28(suppl_4): p. iv1-iv21.

  23. Fleisher, L.A., et al., ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation, 2007. 116(17): p. e418-99.

  24. Poldermans, D., et al., Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). Eur J Anaesthesiol, 2010. 27(2): p. 92-137.

  25. Naidich, D.P., et al., Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. Radiology, 2013. 266(1): p. 304-17.

  26. Eisenhauer, E.A., et al., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 2009. 45(2): p. 228-47.

  27. Leroy, V., et al., Pembrolizumab-induced pneumonitis. ERJ Open Res, 2017. 3(2).

  28. Alberts, W.M. and A.C.o.C. Physicians, Diagnosis and management of lung cancer executive summary: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest, 2007. 132(3 Suppl): p. 1S-19S.

  29. De Wever, W., et al., Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration. Eur Respir J, 2009. 33(1): p. 201-12.

  30. Ambrosini, V., et al., PET/CT imaging in different types of lung cancer: an overview. Eur J Radiol, 2012. 81(5): p. 988-1001.

  31. Guerra, L., et al., Respiratory gated PET/CT in a European multicentre retrospective study: added diagnostic value in detection and characterization of lung lesions. Eur J Nucl Med Mol Imaging, 2012. 39(9): p. 1381-90.

  32. Bastarrika, G., et al., Early lung cancer detection using spiral computed tomography and positron emission tomography. Am J Respir Crit Care Med, 2005. 171(12): p. 1378-83.

  33. Bunyaviroch, T. and R.E. Coleman, PET evaluation of lung cancer. J Nucl Med, 2006. 47(3): p. 451-69.

  34. Silvestri, G.A., et al., Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest, 2007. 132(3 Suppl): p. 178S-201S.

  35. Takamochi, K., et al., Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients. Lung Cancer, 2005. 47(2): p. 235-42.

  36. Perigaud, C., et al., Prospective preoperative mediastinal lymph node staging by integrated positron emission tomography-computerised tomography in patients with non-small-cell lung cancer. Eur J Cardiothorac Surg, 2009. 36(4): p. 731-6.

  37. Søgaard, R., et al., Preoperative staging of lung cancer with PET/CT: cost-effectiveness evaluation alongside a randomized controlled trial. Eur J Nucl Med Mol Imaging, 2011. 38(5): p. 802-9.

  38. Langer, A., A systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a cost-effective manner? BMC Health Serv Res, 2010. 10: p. 283.

  39. MacManus, M., et al., Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol, 2009. 91(1): p. 85-94.

  40. Oh, J.R., et al., Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer. Eur J Nucl Med Mol Imaging, 2012. 39(6): p. 925-35.

  41. Shirvani, S.M., et al., Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys, 2012. 82(1): p. e91-7.

  42. van Loon, J., et al., Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys, 2010. 77(2): p. 329-36.

  43. Adams, R.F., et al., Percutaneous image-guided cutting needle biopsy of the pleura in the diagnosis of malignant mesothelioma. Chest, 2001. 120(6): p. 1798-802.

  44. Goeckenjan, G., et al., Prevention, diagnosis, therapy, and follow-up of lung cancer: interdisciplinary guideline of the German Respiratory Society and the German Cancer Society. Pneumologie, 2011. 65(1): p. 39-59.

  45. Johnson, P.T., K.M. Horton, and E.K. Fishman, Adrenal mass imaging with multidetector CT: pathologic conditions, pearls, and pitfalls. Radiographics, 2009. 29(5): p. 1333-51.

  46. Nishino, M., et al., Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res, 2013. 19(14): p. 3936-43.

  47. Chalian, H., et al., Radiologic assessment of response to therapy: comparison of RECIST Versions 1.1 and 1.0. Radiographics, 2011. 31(7): p. 2093-105.

  48. Schneider, J., Tumor markers in detection of lung cancer. Adv Clin Chem, 2006. 42: p. 1-41.

  49. Stovold, R., et al., Biomarkers for small cell lung cancer: neuroendocrine, epithelial and circulating tumour cells. Lung Cancer, 2012. 76(3): p. 263-8.

  50. D'Urso, V., et al., Sputum analysis: non-invasive early lung cancer detection. J Cell Physiol, 2013. 228(5): p. 945-51.

  51. Roth, K., et al., Cost minimization analysis for combinations of sampling techniques in bronchoscopy of endobronchial lesions. Respir Med, 2009. 103(6): p. 888-94.

  52. Roth, K., et al., Predictors of diagnostic yield in bronchoscopy: a retrospective cohort study comparing different combinations of sampling techniques. BMC Pulm Med, 2008. 8: p. 2.

  53. Tan, B.B., et al., The solitary pulmonary nodule. Chest, 2003. 123(1 Suppl): p. 89S-96S.

  54. Herth, F., H.D. Becker, and A. Ernst, Conventional vs endobronchial ultrasound-guided transbronchial needle aspiration: a randomized trial. Chest, 2004. 125(1): p. 322-5.

  55. Du Rand, I.A., et al., British Thoracic Society guideline for advanced diagnostic and therapeutic flexible bronchoscopy in adults. Thorax, 2011. 66 Suppl 3: p. iii1-21.

  56. Herth, F.J., et al., Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically and positron emission tomography-normal mediastinum in patients with lung cancer. Chest, 2008. 133(4): p. 887-91.

  57. Herth, F.J., et al., Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically normal mediastinum. Eur Respir J, 2006. 28(5): p. 910-4.

  58. Lee, H.S., et al., Real-time endobronchial ultrasound-guided transbronchial needle aspiration in mediastinal staging of non-small cell lung cancer: how many aspirations per target lymph node station? Chest, 2008. 134(2): p. 368-74.

  59. Griffin, A.C., L.E. Schwartz, and Z.W. Baloch, Utility of on-site evaluation of endobronchial ultrasound-guided transbronchial needle aspiration specimens. Cytojournal, 2011. 8: p. 20.

  60. Konge, L., et al., Reliable and valid assessment of competence in endoscopic ultrasonography and fine-needle aspiration for mediastinal staging of non-small cell lung cancer. Endoscopy, 2012. 44(10): p. 928-33.

  61. Manhire, A.R., C.M. Richardson, and F.V. Gleeson, Lung biopsy guidelines--for the obedience of fools and guidance of wise men. Thorax, 2003. 58(11): p. 913-4.

  62. Manhire, A., et al., Guidelines for radiologically guided lung biopsy. Thorax, 2003. 58(11): p. 920-36.

  63. Skulberg, A.K., L.C. Mathisen, and G. Vaagbø, [Treatment of air embolisms]. Tidsskr Nor Laegeforen, 2016. 136(12-13): p. 1070.

  64. Sharples, L.D., et al., Clinical effectiveness and cost-effectiveness of endobronchial and endoscopic ultrasound relative to surgical staging in potentially resectable lung cancer: results from the ASTER randomised controlled trial. Health Technol Assess, 2012. 16(18): p. 1-75, iii-iv.

  65. Milano, M.T., et al., Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys, 2012. 83(3): p. 878-86.

  66. Annema, J.T., et al., Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial. JAMA, 2010. 304(20): p. 2245-52.

  67. Munavvar, M., et al., The autoclavable semirigid thoracoscope: the way forward in pleural disease? Eur Respir J, 2007. 29(3): p. 571-4.

  68. Bhattacharya, S., et al., Closed pleural biopsy is still useful in the evaluation of malignant pleural effusion. J Lab Physicians, 2012. 4(1): p. 35-8.

  69. Travis, W.D., et al., WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. 2015, Lyon: International Agency for Research on Cancer.

  70. Detterbeck, F.C., et al., The IASLC Lung Cancer Staging Project: Summary of Proposals for Revisions of the Classification of Lung Cancers with Multiple Pulmonary Sites of Involvement in the Forthcoming Eighth Edition of the TNM Classification. J Thorac Oncol, 2016. 11(5): p. 639-650.

  71. Travis, W.D., et al., Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. J Thorac Oncol, 2015. 10(9): p. 1240-2.

  72. Liu, X., et al., Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations. J Clin Oncol, 2015.

  73. Makino, T., et al., Comprehensive Biomarkers for Personalized Treatment in Pulmonary Large Cell Neuroendocrine Carcinoma: A Comparative Analysis With Adenocarcinoma. Ann Thorac Surg, 2016. 102(5): p. 1694-1701.

  74. Le, X., et al., De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors. Lung Cancer, 2015. 88(1): p. 70-3.

  75. Karlsson, A., et al., Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer. Oncotarget, 2015. 6(26): p. 22028-37.

  76. Tsuruoka, K., et al., PD-L1 expression in neuroendocrine tumors of the lung. Lung Cancer, 2017. 108: p. 115-120.

  77. Lund-Iversen, M., et al., NUT expression in primary lung tumours. Diagn Pathol, 2015. 10: p. 156.

  78. Kalemkerian, G.P., et al., Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol, 2018. 36(9): p. 911-919.

  79. Planchard, D., et al., Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2019. 30(5): p. 863-870.

  80. Skov, B.G. and T. Skov, Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx. Appl Immunohistochem Mol Morphol, 2017. 25(7): p. 453-459.

  81. Aguilar, E., et al., Outcomes in NSCLC Patients Treated with First-Line Pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 0-89% vs 90-100%. J Thorac Oncol, 2018. 13(10): p. S367-S368.

  82. Soda, M., et al., Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 2007. 448(7153): p. 561-6.

  83. Vidal, J., et al., Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patients. J Thorac Oncol, 2014. 9(12): p. 1816-20.

  84. Blackhall, F.H., et al., Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. J Clin Oncol, 2014. 32(25): p. 2780-7.

  85. Rodig, S.J., et al., Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res, 2009. 15(16): p. 5216-23.

  86. Hallberg, B. and R.H. Palmer, Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer, 2013. 13(10): p. 685-700.

  87. Kobayashi, S., et al., Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol, 2013. 8(1): p. 45-51.

  88. Kwak, E.L., et al., Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med, 2010. 363(18): p. 1693-703.

  89. Bergethon, K., et al., ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol, 2012. 30(8): p. 863-70.

  90. Gold, K.A., ROS1--targeting the one percent in lung cancer. N Engl J Med, 2014. 371(21): p. 2030-1.

  91. Lin, J.J. and A.T. Shaw, Recent Advances in Targeting ROS1 in Lung Cancer. J Thorac Oncol, 2017. 12(11): p. 1611-1625.

  92. Brustugun, O.T., et al., BRAF-mutations in non-small cell lung cancer. Lung Cancer, 2014. 84(1): p. 36-8.

  93. Roberts, P.J., et al., Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol, 2010. 28(31): p. 4769-77.

  94. Lindeman, N.I., et al., Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol, 2018. 13(3): p. 323-358.

  95. Wan, J.C., et al., Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer, 2017. 17(4): p. 223-238.

  96. Merker, J.D., et al., Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol, 2018. 36(16): p. 1631-1641.

  97. Abbosh, C., N.J. Birkbak, and C. Swanton, Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection. Nat Rev Clin Oncol, 2018. 15(9): p. 577-586.

  98. Remon, J., et al., Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA. Ann Oncol, 2017. 28(4): p. 784-790.

  99. Hansell, D.M., et al., Fleischner Society: glossary of terms for thoracic imaging. Radiology, 2008. 246(3): p. 697-722.

  100. MacMahon, H., et al., Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology, 2017. 284(1): p. 228-243.

  101. Park, E.A., et al., Efficacy of computer-aided detection system and thin-slab maximum intensity projection technique in the detection of pulmonary nodules in patients with resected metastases. Invest Radiol, 2009. 44(2): p. 105-13.

  102. Truong, M.T., et al., Update in the evaluation of the solitary pulmonary nodule. Radiographics, 2014. 34(6): p. 1658-79.

  103. Gould, M.K., et al., Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2013. 143(5 Suppl): p. e93S-120S.

  104. Godoy, M.C. and D.P. Naidich, Overview and strategic management of subsolid pulmonary nodules. J Thorac Imaging, 2012. 27(4): p. 240-8.

  105. Travis, W.D., et al., The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer. J Thorac Oncol, 2016. 11(8): p. 1204-1223.

  106. Chung, J.H., et al., Epidermal growth factor receptor mutation and pathologic-radiologic correlation between multiple lung nodules with ground-glass opacity differentiates multicentric origin from intrapulmonary spread. J Thorac Oncol, 2009. 4(12): p. 1490-5.

  107. Park, C.M., et al., Pulmonary nodular ground-glass opacities in patients with extrapulmonary cancers: what is their clinical significance and how can we determine whether they are malignant or benign lesions? Chest, 2008. 133(6): p. 1402-9.

  108. Ashraf, H., et al., Combined use of positron emission tomography and volume doubling time in lung cancer screening with low-dose CT scanning. Thorax, 2011. 66(4): p. 315-9.

  109. MacMahon, H., et al., Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology, 2005. 237(2): p. 395-400.

  110. Callister, M.E., et al., British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax, 2015. 70 Suppl 2: p. ii1-ii54.

  111. Bankier, A.A., et al., Recommendations for Measuring Pulmonary Nodules at CT: A Statement from the Fleischner Society. Radiology, 2017. 285(2): p. 584-600.

  112. Wilson, J.M. and Y.G. Jungner, [Principles and practice of mass screening for disease]. Bol Oficina Sanit Panam, 1968. 65(4): p. 281-393.

  113. Pedersen, J.H., et al., Implementation of lung cancer CT screening in the Nordic countries. Acta Oncol, 2017. 56(10): p. 1249-1257.

  114. Spiro, S.G., Screening for lung cancer: we still need to know more. Thorax, 2012. 67(4): p. 283-5.

  115. Saghir, Z., et al., CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT. Thorax, 2012. 67(4): p. 296-301.

  116. Aberle, D.R., et al., Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med, 2011. 365(5): p. 395-409.

  117. Aberle, D.R., et al., Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med, 2013. 369(10): p. 920-31.

  118. Dominioni, L., et al., A population-based cohort study of chest x-ray screening in smokers: lung cancer detection findings and follow-up. BMC Cancer, 2012. 12: p. 18.

  119. Oken, M.M., et al., Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA, 2011. 306(17): p. 1865-73.

  120. Field, J.K., et al., European randomized lung cancer screening trials: Post NLST. J Surg Oncol, 2013. 108(5): p. 280-6.

  121. Pedersen, J.H., et al., Implementation of Lung Cancer CT Screening in the  Nordic Countries. Acta Oncol, 2017: p. in press.

  122. Kauczor, H.U., et al., ESR/ERS white paper on lung cancer screening. Eur Respir J, 2015. 46(1): p. 28-39.

  123. Brunelli, A., C. Pompili, and M. Salati, Low-technology exercise test in the preoperative evaluation of lung resection candidates. Monaldi Arch Chest Dis, 2010. 73(2): p. 72-8.

  124. Vilmann, P., et al., Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). Endoscopy, 2015. 47(6): p. c1.

  125. Warren, G.W., et al., The 2014 Surgeon General's report: "The health consequences of smoking--50 years of progress": a paradigm shift in cancer care. Cancer, 2014. 120(13): p. 1914-6.

  126. Al-Sahaf, M. and E. Lim, The association between surgical volume, survival and quality of care. J Thorac Dis, 2015. 7(Suppl 2): p. S152-5.

  127. Refai, M., et al., Efficacy of anterior fissureless technique for right upper lobectomies: a case-matched analysis. Eur J Cardiothorac Surg, 2011. 39(6): p. 1043-6.

  128. Albain, K.S., et al., Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet, 2009. 374(9687): p. 379-86.

  129. van Meerbeeck, J.P., et al., Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst, 2007. 99(6): p. 442-50.

  130. Francis, S., et al., Sequencing of Postoperative Radiotherapy and Chemotherapy for Locally Advanced or Incompletely Resected Non-Small-Cell Lung Cancer. J Clin Oncol, 2017: p. JCO2017744771.

  131. Weichselbaum, R.R. and S. Hellman, Oligometastases revisited. Nat Rev Clin Oncol, 2011. 8(6): p. 378-82.

  132. Hishida, T., et al., Is surgical resection indicated for a solitary non-small cell lung cancer recurrence? J Thorac Cardiovasc Surg, 2006. 131(4): p. 838-842.

  133. Veronesi, G., et al., Robot-assisted surgery for lung cancer: State of the art and perspectives. Lung Cancer, 2016. 101: p. 28-34.

  134. Berry, M.F., et al., Thoracoscopic approach to lobectomy for lung cancer does not compromise oncologic efficacy. Ann Thorac Surg, 2014. 98(1): p. 197-202.

  135. Falcoz, P.E., et al., Video-assisted thoracoscopic surgery versus open lobectomy for primary non-small-cell lung cancer: a propensity-matched analysis of outcome from the European Society of Thoracic Surgeon database. Eur J Cardiothorac Surg, 2015.

  136. McKenna, R.J., et al., Wedge resection and brachytherapy for lung cancer in patients with poor pulmonary function. Ann Thorac Surg, 2008. 85(2): p. 733-736.

  137. Kodama, K., et al., Intentional limited resection for selected patients with T1 N0 M0 non-small-cell lung cancer: a single-institution study. J Thorac Cardiovasc Surg, 1997. 114(3): p. 347-353.

  138. De Ruysscher, D., K. Nakagawa, and H. Asamura, Surgical and nonsurgical approaches to small-size nonsmall cell lung cancer. Eur Respir J, 2014. 44(2): p. 483-94.

  139. Ferguson, M.K. and A.G. Lehman, Sleeve lobectomy or pneumonectomy: optimal management strategy using decision analysis techniques. Ann Thorac Surg, 2003. 76(6): p. 1782-1788.

  140. Lakha, S., et al., Prognostic significance of visceral pleural involvement in early-stage lung cancer. Chest, 2014. 146(6): p. 1619-1626.

  141. Chang, J.Y., et al., Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol, 2015.

  142. Corso, C.D., et al., Re-evaluation of the role of postoperative radiotherapy and the impact of radiation dose for non-small-cell lung cancer using the National Cancer Database. J Thorac Oncol, 2015. 10(1): p. 148-55.

  143. Wang, E.H., et al., Postoperative Radiation Therapy Is Associated With Improved Overall Survival in Incompletely Resected Stage II and III Non-Small-Cell Lung Cancer. J Clin Oncol, 2015. 33(25): p. 2727-34.

  144. Baumann, P., et al., Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol, 2009. 27(20): p. 3290-3296.

  145. Nantavithya, C., et al., Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys, 2018. 101(3): p. 558-563.

  146. Liao, Z., et al., Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol, 2018. 36(18): p. 1813-1822.

  147. Mesko, S. and D. Gomez, Proton Therapy in Non-small Cell Lung Cancer. Curr Treat Options Oncol, 2018. 19(12): p. 76.

  148. Haasbeek, C.J.A., et al., Critical review of nonsurgical treatment options for stage I non-small cell lung cancer. Oncologist, 2008. 13(3): p. 309-319.

  149. von Meyenfeldt, E.M., et al., Local progression after radiofrequency ablation for pulmonary metastases. Cancer, 2011. 117(16): p. 3781-7.

  150. Arriagada, R., et al., Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med, 2004. 350(4): p. 351-60.

  151. Sedrakyan, A., et al., Postoperative chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis. 2004. p. 414-419.

  152. Winton, T., et al., Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med, 2005. 352(25): p. 2589-97.

  153. Butts, C.A., et al., Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol, 2010. 28(1): p. 29-34.

  154. Fruh, M., et al., Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J Clin Oncol, 2008. 26(21): p. 3573-3581.

  155. Cuffe, S., et al., Adjuvant chemotherapy for non-small-cell lung cancer in the elderly: a population-based study in Ontario, Canada. J Clin Oncol, 2012. 30(15): p. 1813-21.

  156. Genova, C., E. Rijavec, and F. Grossi, Hematopoietic growth factors in lung cancer. Curr Opin Oncol, 2016. 28(2): p. 135-44.

  157. Song, W.A., et al., Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials. J Thorac Oncol, 2010. 5(4): p. 510-6.

  158. Hanna, N., et al., Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol, 2008. 26(35): p. 5755-60.

  159. Kelly, K., et al., Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol, 2008. 26(15): p. 2450-6.

  160. Aupérin, A., et al., Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol, 2010. 28(13): p. 2181-90.

  161. Antonia, S.J., et al., Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med, 2017. 377(20): p. 1919-1929.

  162. Antonia, S.J., et al., Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med, 2018. 379(24): p. 2342-2350.

  163. Bi, N. and L. Wang, Superiority of concomitant chemoradiation over sequential chemoradiation in inoperable, locally advanced non-small cell lung cancer: challenges in the selection of appropriate chemotherapy. Semin Radiat Oncol, 2015. 25(2): p. 122-32.

  164. De Ruysscher, D., et al., Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol, 2009. 20(1): p. 98-102.

  165. Bunn, P.A., et al., Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol, 1995. 13(7): p. 1632-41.

  166. Pancoast, H., Superior pulmonary sulcus tumor. JAMA, 1932. 99: p. 1391-6.

  167. Kozower, B.D., et al., Special treatment issues in non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2013. 143(5 Suppl): p. e369S-e399S.

  168. Narayan, S. and C.R. Thomas, Jr., Multimodality therapy for Pancoast tumor. Nat Clin Pract Oncol, 2006. 3(9): p. 484-91.

  169. Rusch, V.W., et al., Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol, 2007. 25(3): p. 313-8.

  170. Rusch, V.W., Management of Pancoast tumours. Lancet Oncol, 2006. 7(12): p. 997-1005.

  171. Nezu, K., et al., Recovery and limitation of exercise capacity after lung resection for lung cancer. Chest, 1998. 113(6): p. 1511-1516.

  172. Fogh, S. and S.S. Yom, Symptom management during the radiation oncology treatment course: a practical guide for the oncology clinician. Semin Oncol, 2014. 41(6): p. 764-75.

  173. Vogelius, I.R. and S.M. Bentzen, A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. Acta Oncol, 2012. 51(8): p. 975-83.

  174. Cannon, D.M., et al., Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. J Clin Oncol, 2013. 31(34): p. 4343-8.

  175. Mehta, V., Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys, 2005. 63(1): p. 5-24.

  176. Stanic, S., et al., No clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236. Int J Radiat Oncol Biol Phys, 2014. 88(5): p. 1092-9.

  177. Baumann, P., et al., Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiother Oncol, 2008. 88(3): p. 359-67.

  178. Simone, C.B., Thoracic Radiation Normal Tissue Injury. Semin Radiat Oncol, 2017. 27(4): p. 370-377.

  179. Mao, J., et al., The impact of induction chemotherapy and the associated tumor response on subsequent radiation-related changes in lung function and tumor response. Int J Radiat Oncol Biol Phys, 2007. 67(5): p. 1360-9.

  180. Chiu, C.H., et al., Usefulness of low-dose spiral CT of the chest in regular follow-up of postoperative non-small cell lung cancer patients: Preliminary report. J Thorac Cardiovasc Surg, 2003. 125(6): p. 1300-5.

  181. Colt, H.G., et al., Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest, 2013. 143(5 Suppl): p. e437S-54S.

  182. Schmidt-Hansen, M., D.R. Baldwin, and E. Hasler, What is the most effective follow-up model for lung cancer patients? A systematic review. J Thorac Oncol, 2012. 7(5): p. 821-4.

  183. Mollberg, N.M. and M.K. Ferguson, Postoperative surveillance for non-small cell lung cancer resected with curative intent: developing a patient-centered approach. Ann Thorac Surg, 2013. 95(3): p. 1112-21.

  184. Rubins, J., et al., Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline (2nd edition). Chest, 2007. 132(3 Suppl): p. 355S-367S.

  185. Sonobe, M., et al., Identification of subsets of patients with favorable prognosis after recurrence in completely resected non-small cell lung cancer. Ann Surg Oncol, 2014. 21(8): p. 2546-54.

  186. Lou, F., et al., Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routine computed tomography surveillance. J Thorac Cardiovasc Surg, 2013. 145(1): p. 75-81; discussion 81-2.

  187. Vansteenkiste, J., et al., 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol, 2014. 25(8): p. 1462-74.

  188. Gorenberg, M., R. Bar-Shalom, and O. Israel, Patterns of FDG uptake in post-thoracotomy surgical scars in patients with lung cancer. Br J Radiol, 2008. 81(970): p. 821-5.

  189. Takenaka, D., et al., Integrated FDG-PET/CT vs. standard radiological examinations: comparison of capability for assessment of postoperative recurrence in non-small cell lung cancer patients. Eur J Radiol, 2010. 74(3): p. 458-64.

  190. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ, 1995. 311(7010): p. 899-909.

  191. Groome, P.A., et al., The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol, 2007. 2(8): p. 694-705.

  192. Gronberg, B.H., et al., Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol, 2009. 27(19): p. 3217-3224.

  193. Helbekkmo, N., et al., Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer, 2007. 97(3): p. 283-9.

  194. von Plessen, C., et al., Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer, 2006. 95(8): p. 966-73.

  195. Janni, W., et al., Study participation improves treatment strategies and individual patient care in participating centers. Anticancer Res, 2006. 26(5B): p. 3661-7.

  196. Fairchild, A., et al., Palliative thoracic radiotherapy for lung cancer: a systematic review. J Clin Oncol, 2008. 26(24): p. 4001-4011.

  197. Sundstrom, S., et al., Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial. J Clin Oncol, 2004. 22(5): p. 801-10.

  198. Strøm, H.H., et al., Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group. Br J Cancer, 2013. 109(6): p. 1467-75.

  199. Falk, S.J., et al., Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trial. BMJ, 2002. 325(7362): p. 465-465.

  200. Sundstrom, S., et al., Immediate or delayed radiotherapy in advanced non-small cell lung cancer (NSCLC)? Data from a prospective randomised study. Radiother Oncol, 2005. 75(2): p. 141-148.

  201. Yamamoto, M., et al., Stereotactic radiosurgery for patients with brain metastases - authors' reply. Lancet Oncol, 2014. 15(7): p. e248.

  202. Brown, P.D., et al., Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol, 2017. 18(8): p. 1049-1060.

  203. Lamba, N., et al., Stereotactic radiosurgery versus whole-brain radiotherapy after intracranial metastasis resection: a systematic review and meta-analysis. Radiat Oncol, 2017. 12(1): p. 106.

  204. Yang, S.Y., et al., Pulmonary resection in patients with nonsmall-cell lung cancer treated with gamma-knife radiosurgery for synchronous brain metastases. Cancer, 2008. 112(8): p. 1780-6.

  205. Suh, J.H., Stereotactic radiosurgery for the management of brain metastases. N Engl J Med, 2010. 362(12): p. 1119-27.

  206. Chen, L., et al., Use of Stereotactic Radiosurgery in Elderly and Very Elderly Patients With Brain Metastases to Limit Toxicity Associated With Whole Brain Radiation Therapy. Int J Radiat Oncol Biol Phys, 2017. 98(4): p. 939-947.

  207. Sadikov, E., et al., Value of whole brain re-irradiation for brain metastases--single centre experience. Clin Oncol (R Coll Radiol), 2007. 19(7): p. 532-8.

  208. Patel, S.H., et al., ACR Appropriateness Criteria® follow-up and retreatment of brain metastases. Am J Clin Oncol, 2012. 35(3): p. 302-6.

  209. Guckenberger, M., et al., Safety and efficacy of stereotactic body radiotherapy as primary treatment for vertebral metastases: a multi-institutional analysis. Radiat Oncol, 2014. 9: p. 226.

  210. Waldeland, E., et al., [Stereotactic irradiation in spinal metastases]. Tidsskr Nor Laegeforen, 2012. 132(22): p. 2478-9.

  211. Nguyen, Q.N., et al., Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases: A Randomized Phase 2 Trial. JAMA Oncol, 2019.

  212. Gandhi, L. and M.C. Garassino, Pembrolizumab plus Chemotherapy in Lung Cancer. N Engl J Med, 2018. 379(11): p. e18.

  213. Borghaei, H., et al., 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. J Thorac Oncol, 2019. 14(1): p. 124-129.

  214. Reck, M., et al., Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med, 2016. 375(19): p. 1823-1833.

  215. Mok, T.S.K., et al., Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, 2019. 393(10183): p. 1819-1830.

  216. Paz-Ares, L., et al., Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med, 2018. 379(21): p. 2040-2051.

  217. Azzoli, C.G., et al., American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol, 2009. 27(36): p. 6251-6266.

  218. Hotta, K., et al., Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer. 2004. p. 3852-3859.

  219. Helbekkmo, N., et al., Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy. Lung Cancer, 2008. 62(2): p. 253-60.

  220. Schiller, J.H., et al., Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 2002. 346(2): p. 92-98.

  221. Goffin, J., et al., First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol, 2010. 5(2): p. 260-74.

  222. Ardizzoni, A., et al., Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst, 2007. 99(11): p. 847-857.

  223. Le Chevalier, T., et al., Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer, 2005. 47(1): p. 69-80.

  224. Barlesi, F. and J.-L. Pujol, Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: a systematic review of phase III trials. Lung Cancer, 2005. 49(3): p. 289-298.

  225. Rajeswaran, A., et al., Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer, 2008. 59(1): p. 1-11.

  226. Jensen, L.H., K. Osterlind, and C. Rytter, Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer, 2008. 62(1): p. 85-91.

  227. Lynch, T.J., et al., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 2004. 350(21): p. 2129-39.

  228. Mok, T.S., et al., Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009. 361(10): p. 947-57.

  229. Rosell, R., et al., Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med, 2009. 361(10): p. 958-967.

  230. Sequist, L.V., et al., Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol, 2013. 31(27): p. 3327-34.

  231. Wu, Y.L., et al., Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol, 2014. 15(2): p. 213-22.

  232. Mitsudomi, T., et al., Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol, 2010. 11(2): p. 121-8.

  233. Maemondo, M., et al., Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 2010. 362(25): p. 2380-8.

  234. Inoue, A., et al., First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol, 2009. 27(9): p. 1394-1400.

  235. Brustugun, O.T., et al., Mutasjonstesting ved ikke-småcellet lungekreft. Tidsskr Nor Laegeforen, 2012. 132(8): p. 952-5.

  236. Helland, Å., et al., EGFR gene alterations in a Norwegian cohort of lung cancer patients selected for surgery. J Thorac Oncol, 2011. 6(5): p. 947-50.

  237. Lilenbaum, R., et al., Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol, 2008. 26(6): p. 863-869.

  238. Gatzemeier, U., et al., Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol, 2007. 25(12): p. 1545-1552.

  239. Herbst, R.S., et al., Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol, 2004. 22(5): p. 785-794.

  240. Park, K., et al., Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol, 2016.

  241. Yang, J.C., et al., Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol, 2015. 16(7): p. 830-8.

  242. Soria, J.C., et al., Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med, 2017.

  243. Soria, J.C., et al., Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol, 2015. 16(8): p. 990-8.

  244. Mok, T.S., et al., Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med, 2017. 376(7): p. 629-640.

  245. Shepherd, F.A., et al., Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 2005. 353(2): p. 123-32.

  246. Garassino, M.C., et al., Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol, 2013. 14(10): p. 981-8.

  247. Socinski, M.A., et al., Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med, 2018. 378(24): p. 2288-2301.

  248. Rittmeyer, A., et al., Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet, 2017. 389(10066): p. 255-265.

  249. Herbst, R.S., et al., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet, 2016. 387(10027): p. 1540-50.

  250. Borghaei, H., et al., Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med, 2015. 373(17): p. 1627-39.

  251. Thatcher, N., et al., Expert consensus on the management of erlotinib-associated cutaneous toxicity in the u.k. Oncologist, 2009. 14(8): p. 840-847.

  252. Gridelli, C., et al., ALK inhibitors in the treatment of advanced NSCLC. Cancer Treat Rev, 2014. 40(2): p. 300-6.

  253. Solomon, B.J., et al., First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med, 2014. 371(23): p. 2167-77.

  254. Shaw, A.T., et al., Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med, 2013. 368(25): p. 2385-94.

  255. Soria, J.C., et al., First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet, 2017. 389(10072): p. 917-929.

  256. Shaw, A.T., et al., Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med, 2014. 370(13): p. 1189-97.

  257. Shaw, A.T., et al., Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol, 2016. 17(2): p. 234-242.

  258. Ou, S.H., et al., Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. J Clin Oncol, 2016. 34(7): p. 661-8.

  259. Peters, S., et al., Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med, 2017.

  260. Kim, D.W., et al., Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol, 2016.

  261. Cho, B.C., et al., ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol, 2017. 12(9): p. 1357-1367.

  262. Planchard, D., et al., Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol, 2016. 17(7): p. 984-93.

  263. Planchard, D., et al., Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol, 2017. 18(10): p. 1307-1316.

  264. Shaw, A.T., et al., Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med, 2014. 371(21): p. 1963-71.

  265. Lim, S.M., et al., Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. J Clin Oncol, 2017. 35(23): p. 2613-2618.

  266. Shaw, A.T., et al., Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol, 2017. 18(12): p. 1590-1599.

  267. Ciuleanu, T., et al., Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Lancet Oncol, 2012. 13(3): p. 300-8.

  268. Gridelli, C., et al., Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol, 2008. 3(4): p. 430-440.

  269. Tassinari, D., et al., Second-line treatments in non-small cell lung cancer. A systematic review of literature and metaanalysis of randomized clinical trials. Chest, 2009. 135(6): p. 1596-1609.

  270. Shepherd, F.A., et al., Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 2000. 18(10): p. 2095-2103.

  271. Di Maio, M., et al., Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol, 2009. 27(11): p. 1836-1843.

  272. Brahmer, J., et al., Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med, 2015. 373(2): p. 123-35.

  273. Johnson, D.B., S. Chandra, and J.A. Sosman, Immune Checkpoint Inhibitor Toxicity in 2018. JAMA, 2018. 320(16): p. 1702-1703.

  274. Garon, E.B., et al., Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med, 2015. 372(21): p. 2018-28.

  275. Gettinger, S., et al., Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study. J Clin Oncol, 2018. 36(17): p. 1675-1684.

  276. Spigel, D., et al., Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC). Ann Oncol, 2017. 28: p. v460-v496.

  277. Fehrenbacher, L., et al., Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet, 2016. 387(10030): p. 1837-46.

  278. Barlesi, F., et al., Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study. Lancet Oncol, 2018.

  279. Antonia, S.J., et al., Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med, 2018.

  280. Teraoka, S., et al., Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study. J Thorac Oncol, 2017. 12(12): p. 1798-1805.

  281. Robert, C., et al., Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. J Clin Oncol, 2018. 36(17): p. 1668-1674.

  282. Arbour, K.C., et al., Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. J Clin Oncol, 2018. 36(28): p. 2872-2878.

  283. Ricciuti, B., et al., Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. J Clin Oncol, 2019: p. JCO1900189.

  284. Leonardi, G.C., et al., Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. J Clin Oncol, 2018. 36(19): p. 1905-1912.

  285. Kennedy, L.C., et al., Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors. J Natl Compr Canc Netw, 2019. 17(6): p. 750-757.

  286. Sandler, A., et al., Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med, 2006. 355(24): p. 2542-2550.

  287. Reck, M., et al., Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol, 2010. 21(9): p. 1804-9.

  288. Reck, M., et al., Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol, 2014. 15(2): p. 143-55.

  289. Garon, E.B., et al., Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet, 2014. 384(9944): p. 665-73.

  290. Tsuya, A., et al., Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer, 2007. 57(2): p. 229-232.

  291. Hendriks, L.E., et al., Effect of Bisphosphonates, Denosumab, and Radioisotopes on Bone Pain and Quality of Life in Patients with Non-Small Cell Lung Cancer and Bone Metastases: A Systematic Review. J Thorac Oncol, 2016. 11(2): p. 155-73.

  292. Bolliger, C.T., et al., Therapeutic bronchoscopy with immediate effect: laser, electrocautery, argon plasma coagulation and stents. Eur Respir J, 2006. 27(6): p. 1258-1271.

  293. Wahidi, M.M., et al., Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest, 2007. 132(3 Suppl): p. 94S-107S.

  294. Vergnon, J.M., R.M. Huber, and K. Moghissi, Place of cryotherapy, brachytherapy and photodynamic therapy in therapeutic bronchoscopy of lung cancers. Eur Respir J, 2006. 28(1): p. 200-218.

  295. Ernst, A., et al., Central airway obstruction. Am J Respir Crit Care Med, 2004. 169(12): p. 1278-1297.

  296. Cavaliere, S., et al., Endoscopic treatment of malignant airway obstructions in 2,008 patients. Chest, 1996. 110(6): p. 1536-42.

  297. Brokx, H.A.P., et al., Initial bronchoscopic treatment for patients with intraluminal bronchial carcinoids. J Thorac Cardiovasc Surg, 2007. 133(4): p. 973-978.

  298. Reck, M., et al., Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2014. 25 Suppl 3: p. iii27-39.

  299. Vallieres, E., et al., The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol, 2009. 4(9): p. 1049-1059.

  300. Simon, G.R., A. Turrisi, and A.C.o.C. Physicians, Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest, 2007. 132(3 Suppl): p. 324S-339S.

  301. Schreiber, D., et al., Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated? Cancer, 2010. 116(5): p. 1350-7.

  302. Lad, T., et al., A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest, 1994. 106(6 Suppl): p. 320S-323S.

  303. Früh, M., et al., Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2013. 24 Suppl 6: p. vi99-105.

  304. Sørensen, M., et al., Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2010. 21 Suppl 5: p. v120-5.

  305. Schneider, B.J., A. Saxena, and R.J. Downey, Surgery for early-stage small cell lung cancer. J Natl Compr Canc Netw, 2011. 9(10): p. 1132-9.

  306. Ignatius Ou, S.H. and J.A. Zell, The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC 6th TNM Edition. J Thorac Oncol, 2009. 4(3): p. 300-10.

  307. Yu, J.B., et al., Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer. J Thorac Oncol, 2010. 5(2): p. 215-9.

  308. Rostad, H., et al., Small cell lung cancer in Norway. Should more patients have been offered surgical therapy? Eur J Cardiothorac Surg, 2004. 26(4): p. 782-6.

  309. Bischof, M., et al., Surgery and chemotherapy for small cell lung cancer in stages I-II with or without radiotherapy. Strahlenther Onkol, 2007. 183(12): p. 679-684.

  310. Brock, M.V., et al., Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come. J Thorac Cardiovasc Surg, 2005. 129(1): p. 64-72.

  311. Sculier, J.P., et al., Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. Lung Cancer, 1998. 19(2): p. 141-51.

  312. Sundstrom, S., et al., Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol, 2002. 20(24): p. 4665-4672.

  313. Pignon, J.P., et al., A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med, 1992. 327(23): p. 1618-1624.

  314. Pijls-Johannesma, M.C.G., et al., Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev, 2005(1).

  315. Turrisi, A.T., et al., Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med, 1999. 340(4): p. 265-271.

  316. Schild, S.E., et al., Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys, 2004. 59(4): p. 943-951.

  317. Grønberg, B.H., et al., Randomized phase II trial comparing twice daily hyperfractionated with once daily hypofractionated thoracic radiotherapy in limited disease small cell lung cancer. Acta Oncol, 2016. 55(5): p. 591-7.

  318. Auperin, A., et al., Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med, 1999. 341(7): p. 476-84.

  319. Zhu, H., et al., Prophylactic cranial irradiation improved the overall survival of patients with surgically resected small cell lung cancer, but not for stage I disease. Lung Cancer, 2014. 86(3): p. 334-8.

  320. Le Péchoux, C., et al., Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol, 2009. 10(5): p. 467-74.

  321. Wolfson, A.H., et al., Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys, 2011. 81(1): p. 77-84.

  322. Le Péchoux, C., et al., Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). Ann Oncol, 2011. 22(5): p. 1154-63.

  323. Yuen, A.R., et al., Similar outcome of elderly patients in intergroup trial 0096: Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. Cancer, 2000. 89(9): p. 1953-1960.

  324. Rudin, C.M., et al., Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. J Clin Oncol, 2015. 33(34): p. 4106-11.

  325. Cheng, S., et al., Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol, 2007. 2(4): p. 348-354.

  326. Chen, G., et al., Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. J Clin Oncol, 2009. 27(9): p. 1401-4.

  327. O'Brien, M.E., et al., Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol, 2006. 24(34): p. 5441-7.

  328. von Pawel, J., et al., Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol, 1999. 17(2): p. 658-667.

  329. von Pawel, J., et al., Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol, 2001. 19(6): p. 1743-1749.

  330. Amarasena, I.U., et al., Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database Syst Rev, 2008(4).

  331. Okamoto, H., et al., Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer, 2007. 97(2): p. 162-9.

  332. Hermes, A., et al., Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol, 2008. 26(26): p. 4261-4267.

  333. Noda, K., et al., Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med, 2002. 346(2): p. 85-91.

  334. Hanna, N., et al., Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol, 2006. 24(13): p. 2038-2043.

  335. Lara, P.N., et al., Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol, 2009. 27(15): p. 2530-2535.

  336. Slotman, B.J., et al., Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet, 2015. 385(9962): p. 36-42.

  337. Slotman, B., et al., Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med, 2007. 357(7): p. 664-72.

  338. Takahashi, T., et al., Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol, 2017. 18(5): p. 663-671.

  339. Schild, S.E., et al., Prophylactic Cranial Irradiation for Extensive Small-Cell Lung Cancer. J Oncol Pract, 2017. 13(11): p. 732-738.

  340. Eze, C., L. Käsmann, and F. Manapov, Redefining the Role of Prophylactic Cranial Irradiation in the Modern Era of Active Surveillance in Small Cell Lung Cancer. JAMA Oncol, 2019. 5(1): p. 11-12.

  341. Chen, G., et al., Chemotherapy for brain metastases in small-cell lung cancer. Clin Lung Cancer, 2008. 9(1): p. 35-38.

  342. Pelayo Alvarez, M., et al., Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev, 2009(4): p. CD001990.

  343. Thatcher, N., C. Faivre-Finn, and P. Lorigan, Management of small-cell lung cancer. Ann Oncol, 2005. 16 Suppl 2: p. ii235-9.

  344. Walji, N., A.K. Chan, and D.R. Peake, Common acute oncological emergencies: diagnosis, investigation and management. Postgrad Med J, 2008. 84(994): p. 418-427.

  345. Wilson, L.D., F.C. Detterbeck, and J. Yahalom, Clinical practice. Superior vena cava syndrome with malignant causes. N Engl J Med, 2007. 356(18): p. 1862-1869.

  346. Rowell, N.P. and F.V. Gleeson, Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus. Cochrane Database Syst Rev, 2001(4): p. CD001316.

  347. Reveiz, L., J.R. Rueda, and A.F. Cardona, Palliative endobronchial brachytherapy for non-small cell lung cancer. Cochrane Database Syst Rev, 2012. 12: p. CD004284.

  348. Ropper, A.E. and A.H. Ropper, Acute Spinal Cord Compression. N Engl J Med, 2017. 376(14): p. 1358-1369.

  349. George, R., et al., Interventions for the treatment of metastatic extradural spinal cord compression in adults. Cochrane Database Syst Rev, 2015(9): p. CD006716.

  350. Kumar, A., et al., Metastatic Spinal Cord Compression and Steroid Treatment: A Systematic Review. Clin Spine Surg, 2017. 30(4): p. 156-163.

  351. Sørensen, S., et al., Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer, 1994. 30A(1): p. 22-7.

  352. Patchell, R.A., et al., Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet, 2005. 366(9486): p. 643-8.

  353. Saunders, Y., et al., Systematic review of bisphosphonates for hypercalcaemia of malignancy. 2004. p. 418-431.

  354. Lyman, G.H., et al., Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol, 2015. 33(6): p. 654-6.

  355. Rubin, L.G., et al., 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis, 2014. 58(3): p. e44-100.

  356. Cherny, N.I., et al., ESMO takes a stand on supportive and palliative care. Ann Oncol, 2003. 14(9): p. 1335-7.

  357. Ferris, F.D., et al., Palliative cancer care a decade later: accomplishments, the need, next steps -- from the American Society of Clinical Oncology. J Clin Oncol, 2009. 27(18): p. 3052-8.

  358. Polanski, J., et al., Quality of life of patients with lung cancer. Onco Targets Ther, 2016. 9: p. 1023-8.

  359. Temel, J.S., et al., Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med, 2010. 363(8): p. 733-42.

  360. Hui, D. and E. Bruera, Integrating palliative care into the trajectory of cancer care. Nat Rev Clin Oncol, 2016. 13(3): p. 159-71.

  361. Kaasa, S., et al., Integration of oncology and palliative care: a Lancet Oncology Commission. Lancet Oncol, 2018. 19(11): p. e588-e653.

  362. Calvert, M., et al., Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA, 2013. 309(8): p. 814-22.

  363. Watanabe, S.M., C.L. Nekolaichuk, and C. Beaumont, The Edmonton Symptom Assessment System, a proposed tool for distress screening in cancer patients: development and refinement. Psychooncology, 2012. 21(9): p. 977-85.

  364. Payne, C., et al., Exercise and nutrition interventions in advanced lung cancer: a systematic review. Curr Oncol, 2013. 20(4): p. e321-37.

  365. Chandrasekar, D., E. Tribett, and K. Ramchandran, Integrated Palliative Care and Oncologic Care in Non-Small-Cell Lung Cancer. Curr Treat Options Oncol, 2016. 17(5): p. 23.

  366. Arends, J., et al., ESPEN guidelines on nutrition in cancer patients. Clin Nutr, 2017. 36(1): p. 11-48.

  367. Edvardsen, E., et al., High-intensity training following lung cancer surgery: a randomised controlled trial. Thorax, 2015. 70(3): p. 244-50.

  368. Brown, D.J., Palliation of breathlessness. Clin Med (Lond), 2006. 6(2): p. 133-6.

  369. Jennings, A.L., et al., A systematic review of the use of opioids in the management of dyspnoea. Thorax, 2002. 57(11): p. 939-44.

  370. Grassi, L., et al., The use of antidepressants in oncology: a review and practical tips for oncologists. Ann Oncol, 2018. 29(1): p. 101-111.

  371. Fernandez-Cuesta, L., et al., Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nat Commun, 2014. 5: p. 3518.

  372. Caplin, M.E., et al., Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol, 2015.

  373. Wolin, E.M., Advances in the Diagnosis and Management of Well-Differentiated and Intermediate-Differentiated Neuroendocrine Tumors of the Lung. Chest, 2017. 151(5): p. 1141-1146.

  374. Klimstra, D.S., et al., The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas, 2010. 39(6): p. 707-12.

  375. Oberg, K. and D. Castellano, Current knowledge on diagnosis and staging of neuroendocrine tumors. Cancer Metastasis Rev, 2011. 30 Suppl 1: p. 3-7.

  376. Boyar Cetinkaya, R., et al., Trends in Incidence of Neuroendocrine Neoplasms in Norway: A Report of 16,075 Cases from 1993 through 2010. Neuroendocrinology, 2017. 104(1): p. 1-10.

  377. Detterbeck, F.C., Management of carcinoid tumors. Ann Thorac Surg, 2010. 89(3): p. 998-1005.

  378. Harpole, D.H., et al., Bronchial carcinoid tumors: a retrospective analysis of 126 patients. Ann Thorac Surg, 1992. 54(1): p. 50-4; discussion 54-5.

  379. Fink, G., et al., Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest, 2001. 119(6): p. 1647-51.

  380. Moore, W., et al., FDG-PET imaging in patients with pulmonary carcinoid tumor. Clin Nucl Med, 2013. 38(7): p. 501-5.

  381. Korse, C.M., et al., Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments. Eur J Cancer, 2012. 48(5): p. 662-71.

  382. Filosso, P.L., et al., Outcome and prognostic factors in bronchial carcinoids: a single-center experience. J Thorac Oncol, 2013. 8(10): p. 1282-8.

  383. Cardillo, G., et al., Bronchial carcinoid tumors: nodal status and long-term survival after resection. Ann Thorac Surg, 2004. 77(5): p. 1781-5.

  384. Wirth, L.J., et al., Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer, 2004. 44(2): p. 213-20.

  385. Cañizares, M.A., et al., Atypical carcinoid tumours of the lung: prognostic factors and patterns of recurrence. Thorax, 2014. 69(7): p. 648-53.

  386. Anderson, K.L., et al., Adjuvant Chemotherapy Does Not Confer Superior Survival in Patients With Atypical Carcinoid Tumors. Ann Thorac Surg, 2017. 104(4): p. 1221-1230.

  387. Nussbaum, D.P., et al., Defining the role of adjuvant chemotherapy after lobectomy for typical bronchopulmonary carcinoid tumors. Ann Thorac Surg, 2015. 99(2): p. 428-34.

  388. Neyman, K., et al., Endoscopic treatment of bronchial carcinoids in comparison to surgical resection: a retrospective study. J Bronchology Interv Pulmonol, 2012. 19(1): p. 29-34.

  389. Strosberg, J., et al., Phase 3 Trial of. N Engl J Med, 2017. 376(2): p. 125-135.

  390. Granberg, D., et al., Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol, 2001. 12(10): p. 1383-91.

  391. Yao, J.C., et al., Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet, 2016. 387(10022): p. 968-977.

  392. Crona, J., et al., Effect of temozolomide in patients with metastatic bronchial carcinoids. Neuroendocrinology, 2013. 98(2): p. 151-5.

  393. Kulke, M.H., et al., Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol, 2008. 26(20): p. 3403-10.

  394. Moertel, C.G., et al., Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer, 1991. 68(2): p. 227-32.

  395. Moertel, C.G. and J.A. Hanley, Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials, 1979. 2(4): p. 327-34.

  396. Mackley, H.B. and G.M. Videtic, Primary carcinoid tumors of the lung: a role for radiotherapy. Oncology (Williston Park), 2006. 20(12): p. 1537-43; discussion 1544-5, 1549.

  397. Travis, W.D., Pathology and diagnosis of neuroendocrine tumors: lung neuroendocrine. Thorac Surg Clin, 2014. 24(3): p. 257-66.

  398. Gollard, R., et al., Large cell/neuroendocrine carcinoma. Lung Cancer, 2010. 69(1): p. 13-8.

  399. Rossi, G., et al., Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol, 2005. 23(34): p. 8774-85.

  400. Iyoda, A., et al., Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma. J Thorac Cardiovasc Surg, 2009. 138(2): p. 446-53.

  401. Le Treut, J., et al., Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. Ann Oncol, 2013. 24(6): p. 1548-52.

  402. Veronesi, G., et al., Large cell neuroendocrine carcinoma of the lung: a retrospective analysis of 144 surgical cases. Lung Cancer, 2006. 53(1): p. 111-5.

  403. Saji, H., et al., Clinical response of large cell neuroendocrine carcinoma of the lung to perioperative adjuvant chemotherapy. Anticancer Drugs, 2010. 21(1): p. 89-93.

  404. Yamazaki, S., et al., Clinical responses of large cell neuroendocrine carcinoma of the lung to cisplatin-based chemotherapy. Lung Cancer, 2005. 49(2): p. 217-23.

  405. Igawa, S., et al., Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer. Lung Cancer, 2010. 68(3): p. 438-45.

  406. Sun, J.M., et al., Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer? Lung Cancer, 2012. 77(2): p. 365-70.

  407. Kozuki, T., et al., Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma. J Cancer Res Clin Oncol, 2005. 131(3): p. 147-51.

  408. Oberg, K., et al., Neuroendocrine bronchial and thymic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2010. 21 Suppl 5: p. v220-2.

  409. Rieber, J., et al., Outcome and prognostic factors of multimodal therapy for pulmonary large-cell neuroendocrine carcinomas. Eur J Med Res, 2015. 20: p. 64.

  410. Robinson, B.W. and R.A. Lake, Advances in malignant mesothelioma. N Engl J Med, 2005. 353(15): p. 1591-603.

  411. Ulvestad, B., et al., Incidence trends of mesothelioma in Norway, 1965-1999. Int J Cancer, 2003. 107(1): p. 94-98.

  412. Helland, Å., S. Solberg, and O.T. Brustugun, Incidence and survival of malignant pleural mesothelioma in norway: a population-based study of 1686 cases. J Thorac Oncol, 2012. 7(12): p. 1858-61.

  413. Tsao, A.S., et al., Malignant pleural mesothelioma. J Clin Oncol, 2009. 27(12): p. 2081-90.

  414. Yates, D.H., et al., Malignant mesothelioma in south east England: clinicopathological experience of 272 cases. Thorax, 1997. 52(6): p. 507-512.

  415. Ray, M. and H.L. Kindler, Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest, 2009. 136(3): p. 888-96.

  416. Scherpereel, A., et al., Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J, 2010. 35(3): p. 479-95.

  417. Kao, S.C., et al., Accuracy of diagnostic biopsy for the histological subtype of malignant pleural mesothelioma. J Thorac Oncol, 2011. 6(3): p. 602-5.

  418. Truong, M.T., et al., Malignant pleural mesothelioma: role of CT, MRI, and PET/CT in staging evaluation and treatment considerations. Semin Roentgenol, 2013. 48(4): p. 323-34.

  419. Hollevoet, K., et al., Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol, 2012. 30(13): p. 1541-9.

  420. Husain, A.N., et al., Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med, 2013. 137(5): p. 647-67.

  421. Chirieac, L.R., et al., The immunohistochemical characterization of sarcomatoid malignant mesothelioma of the pleura. Am J Cancer Res, 2011. 1(1): p. 14-24.

  422. Rusch, V.W., et al., The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma. J Thorac Oncol, 2016. 11(12): p. 2112-2119.

  423. Flores, R.M., et al., Positron emission tomography predicts survival in malignant pleural mesothelioma. J Thorac Cardiovasc Surg, 2006. 132(4): p. 763-768.

  424. Sorensen, J.B., et al., Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy. Eur J Cardiothorac Surg, 2008. 34(5): p. 1090-1096.

  425. Rice, D.C., et al., Endoscopic ultrasound-guided fine needle aspiration for staging of malignant pleural mesothelioma. Ann Thorac Surg, 2009. 88(3): p. 862-8; discussion 868-9.

  426. Stahel, R.A., et al., Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2010. 21 Suppl 5: p. v126-8.

  427. Sugarbaker, D.J., et al., Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg, 1999. 117(1): p. 54-63.

  428. Treasure, T., et al., Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol, 2011. 12(8): p. 763-72.

  429. de Perrot, M., et al., Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol, 2009. 27(9): p. 1413-8.

  430. Krug, L.M., et al., Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol, 2009. 27(18): p. 3007-13.

  431. Weder, W., et al., Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol, 2007. 18(7): p. 1196-202.

  432. Cao, C.Q., et al., A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol, 2010. 5(10): p. 1692-703.

  433. Bissett, D., F.R. Macbeth, and I. Cram, The role of palliative radiotherapy in malignant mesothelioma. Clin Oncol (R Coll Radiol), 1991. 3(6): p. 315-7.

  434. Holsti, L.R., et al., Altered fractionation of hemithorax irradiation for pleural mesothelioma and failure patterns after treatment. Acta Oncol, 1997. 36(4): p. 397-405.

  435. De Ruysscher, D. and B. Slotman, Treatment of intervention sites of malignant pleural mesothelioma with radiotherapy: a Dutch-Belgian survey. Radiotherapy and Oncology, 2003. 68(3): p. 299-302.

  436. van Thiel, E.R., V.F. Surmont, and J.P. van Meerbeeck, Malignant pleural mesothelioma: when is radiation therapy indicated? Expert Rev Anticancer Ther, 2011. 11(4): p. 551-60.

  437. Waite, K. and D. Gilligan, The role of radiotherapy in the treatment of malignant pleural mesothelioma. Clin Oncol (R Coll Radiol), 2007. 19(3): p. 182-7.

  438. Bydder, S., et al., A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer, 2004. 91(1): p. 9-10.

  439. O'Rourke, N., et al., A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol, 2007. 84(1): p. 18-22.

  440. Kelly, R.J., E. Sharon, and R. Hassan, Chemotherapy and targeted therapies for unresectable malignant mesothelioma. Lung Cancer, 2011. 73(3): p. 256-63.

  441. Ellis, P., et al., The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol, 2006. 1(6): p. 591-601.

  442. Vogelzang, N.J., et al., Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol, 2003. 21(14): p. 2636-2644.

  443. van Meerbeeck, J.P., et al., Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol, 2005. 23(28): p. 6881-9.

  444. Santoro, A., et al., Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol, 2008. 3(7): p. 756-63.

  445. O'Brien, M.E., et al., A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol, 2006. 17(2): p. 270-5.

  446. Zalcman, G., et al., Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet, 2016. 387(10026): p. 1405-14.

  447. Maio, M., et al., Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol, 2017. 18(9): p. 1261-1273.

  448. Hillerdal, G., et al., Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study. J Thorac Oncol, 2008. 3(11): p. 1325-1331.

  449. Shaw, P. and R. Agarwal, Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev, 2004(1).

  450. Anderson, G. and Y. Takahama, Thymic epithelial cells: working class heroes for T cell development and repertoire selection. Trends Immunol, 2012. 33(6): p. 256-63.

  451. Kelly, R.J., Thymoma versus thymic carcinoma: differences in biology impacting treatment. J Natl Compr Canc Netw, 2013. 11(5): p. 577-83.

  452. Masaoka, A., Staging system of thymoma. J Thorac Oncol, 2010. 5(10 Suppl 4): p. S304-12.

  453. Romi, F., Thymoma in myasthenia gravis: from diagnosis to treatment. Autoimmune Dis, 2011. 2011: p. 474512.

  454. Detterbeck, F.C., et al., The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms. J Thorac Oncol, 2011. 6(7 Suppl 3): p. S1710-6.

  455. Ruffini, E., et al., Management of thymic tumors: a survey of current practice among members of the European Society of Thoracic Surgeons. J Thorac Oncol, 2011. 6(3): p. 614-23.

  456. Marom, E.M., Advances in thymoma imaging. J Thorac Imaging, 2013. 28(2): p. 69-80; quiz 81-3.

  457. Ackman, J.B. and C.C. Wu, MRI of the thymus. AJR Am J Roentgenol, 2011. 197(1): p. W15-20.

  458. Romi, F., et al., Muscle autoantibodies in subgroups of myasthenia gravis patients. J Neurol, 2000. 247(5): p. 369-75.

  459. Fujii, Y., Published guidelines for management of thymoma. Thorac Surg Clin, 2011. 21(1): p. 125-9, viii.

  460. Marchevsky, A., et al., Policies and reporting guidelines for small biopsy specimens of mediastinal masses. J Thorac Oncol, 2011. 6(7 Suppl 3): p. S1724-9.

  461. Detterbeck, F.C., et al., Which way is up? Policies and procedures for surgeons and pathologists regarding resection specimens of thymic malignancy. J Thorac Oncol, 2011. 6(7 Suppl 3): p. S1730-8.

  462. Okumura, M., et al., The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer, 2002. 94(3): p. 624-32.

  463. Carter, B.W., et al., IASLC/ITMIG Staging System and Lymph Node Map for Thymic Epithelial Neoplasms. Radiographics, 2017. 37(3): p. 758-776.

  464. Falkson, C.B., et al., The management of thymoma: a systematic review and practice guideline. J Thorac Oncol, 2009. 4(7): p. 911-9.

  465. Komaki, R. and D.R. Gomez, Radiotherapy for Thymic Carcinoma: Adjuvant, Inductive, and Definitive. Front Oncol, 2014. 3: p. 330.

  466. Ruffini, E., et al., Thymic Carcinoma: A Cohort Study of Patients from the European Society of Thoracic Surgeons Database. J Thorac Oncol, 2014. 9: p. 541–548.

  467. Huang, J., et al., Standard outcome measures for thymic malignancies. J Thorac Oncol, 2011. 6(7 Suppl 3): p. S1691-7.

  468. Korst, R.J., et al., Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: a phase II, multi-institutional clinical trial. J Thorac Cardiovasc Surg, 2014. 147(1): p. 36-44, 46.e1.

  469. Hamaji, M., et al., A meta-analysis of debulking surgery versus surgical biopsy for unresectable thymoma. Eur J Cardiothorac Surg, 2015. 47(4): p. 602-7.

  470. Wei, M.L., et al., Chemotherapy for thymic carcinoma and advanced thymoma in adults. Cochrane Database Syst Rev, 2013. 8: p. CD008588.

  471. Cho, J., et al., Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial. J Clin Oncol, 2018: p. JCO2017773184.

  472. Berardi, R., et al., Thymic neoplasms: An update on the use of chemotherapy and new targeted therapies. A literature review. Cancer Treat Rev, 2014. 40(4): p. 495-506.

  473. Loehrer, P.J., et al., Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol, 2004. 22(2): p. 293-9.

  474. Rajan, A., et al., Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol, 2014. 15(2): p. 191-200.

  475. Asamura, H., et al., The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. J Thorac Oncol, 2015. 10(12): p. 1675-84.

  476. Lee, T.H., et al., Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation, 1999. 100(10): p. 1043-9.

  477. Herder, G.J., et al., Clinical prediction model to characterize pulmonary nodules: validation and added value of 18F-fluorodeoxyglucose positron emission tomography. Chest, 2005. 128(4): p. 2490-6.